You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
受益於所有疾病領域增長及罕見病藥物巨頭Alexion加入 阿斯利康(AZN.US)2022上半年收入增長48%
格隆匯 07-29 14:44
格隆匯7月29日丨阿斯利康公佈2022上半年業績,總收入增長了48%達到221.61億美元;包括一筆里程碑付款腫瘤業務總收入增加了22%,其中腫瘤業務產品銷售增長了18%(R&I6的總收入增加了3%,CVRM7增加了19%,罕見病增加了10%)。受益於匯率波動和新冠藥物訂單,核心毛利率為81%。對Alexion 製藥收購以及持續投資,並打造領先行業的具有中長期增長的管線,核心運營利潤率增加33%。由於二季度15%的核心税率,核心每股收益大3.61美元。另外,公司預期2022財年的核心税率預期仍為18-22%。公司中期股息為每股普通股0.93美元。對於2022財年,因新冠藥物前景更新以及整體業務持續強勁表現,使進一步投資成為可能,預計2022年下半年營業收入將與2022上半年類似,每股收益指引不變。首席執行官帕Pascal Soriot表示,阿斯利康在2022年上半年的財務狀況強勁,管線交付狀況表良好。公司公佈了幾種藥物的臨牀數據變化,包括用於治療乳腺癌的Enhertu,用於治療心力衰竭的Farxiga,用於治療視神經脊髓炎的Ultomiris。公司抗擊新冠肺炎疫情取得重大進展。據估計,Vaxzevria疫苗在推出的第一年就挽救了600多萬人的生命,Evusheld疫苗保護了數十萬免疫功能低下的人。Evusheld繼續表現出對抗新變種的活性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account